Trial
NCT02520102
Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Acute Myeloid Leukemia NOS
Intervention
sargramostim GZ402664
Why stopped
Company has fulfilled post-marketing requirements
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-20